Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

OncoImmunology

Volumn 2, Issue 12, 2013, Pages

  Workenhe, Samuel T ^a   Mossman, Karen L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Danger associated molecular patterns; Immunogenic cell death; Mitoxantrone; Oncolytic virus

Indexed keywords

CD40 LIGAND; HIGH MOBILITY GROUP B1 PROTEIN; MITOXANTRONE; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL DEATH; COXSACKIE VIRUS; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; MEASLES VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; SUBCUTANEOUS TISSUE TUMOR; TUMOR IMMUNITY; VIRUS EXPRESSION;

EID: 84894540584     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27138     Document Type: Article

References (10)

1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287
2. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19:329-36; PMID:23396206; http://dx.doi.org/10.1038/nm.3089
3. Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther 2013; Forthcoming; PMID:24048442; http:// dx.doi.org/10.1038/mt.2013.220
4. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/ jem.20050915
5. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http:// dx.doi.org/10.1038/nm1523
6. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
7. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j. immuni.2013.03.003
8. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi. org/10.1038/nrc3380
9. Workenhe ST, Simmon GJ, Pol JG, Lichty BD, Halford WP, Mossman KL. HSV induced immunogenic oncolysis shapes the adaptive immune response and survival after oncolytic HSV-1 treatment. Mol Ther 2013; PMID:24048442
10. Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immunotolerance and improves therapeutic efficacy. Cancer Immunol Res 2013; 1:1-11